Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility.

Autor: Ploem MC; Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Faculty of Law, University of Amsterdam, Amsterdam, the Netherlands., Giesbertz NAA; Department of Genetics, University Medical Center Utrecht, the Netherlands; Department of Clinical Genetics, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Bredenoord AL; Department of Genetics, University Medical Center Utrecht, the Netherlands; Erasmus School of Philosophy, Erasmus University Rotterdam, Rotterdam, the Netherlands., Retèl VP; Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands. Electronic address: v.retel@nki.nl., van Harten WH; Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Health Technology and Services Research, University Twente, Enschede, the Netherlands.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Jun; Vol. 186, pp. 22-26. Date of Electronic Publication: 2023 Mar 10.
DOI: 10.1016/j.ejca.2023.03.004
Abstrakt: Tumour DNA and germline testing, based on DNA-wide sequencing analysis, are becoming more and more routine in clinical-oncology practice. A promising step in medicine, but at the same time leading to challenging ethicolegal questions. An important one is under what conditions individuals (patients and their relatives, research participants) should be recontacted with new information, even if many years have passed since the last contact. Based on legal- and ethical study, we developed a tool to help professionals to decide whether or not to recontact an individual in specific cases. It is based on four assessment criteria: (1) professional relationship (2) clinical impact (3) individual's preferences and (4) feasibility. The tool could also serve as a framework for guidelines on the topic.
Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors have nothing to disclose for the work under consideration for publication. Prof. dr. van Harten reported non-restricted grants from Novartis, Intuitive Surgical and Agendia all ending over three years ago, Dr. Retèl reported non-restricted grants from Intuitive and Agendia outside the submitted work all ending over 3 years ago. The other authors have nothing to declare.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: